All Updates

All Updates

icon
Filter
Partnerships
Tempus AI collaborates with United Therapeutics to develop AI-based risk detection for pulmonary hypertension
Precision Medicine
Jun 25, 2024
This week:
Partnerships
MGI Tech and Predica Diagnostics collaborate to develop Predica's targeted RNA sequencing tests
Precision Medicine
Yesterday
Partnerships
Renalytix partners with Steno Diabetes Center to advance precision medicine solutions for diabetes and chronic kidney disease
Precision Medicine
Yesterday
Partnerships
Myriad Genetics and Personalis cross-license patents for tumor-informed cancer treatment tests
Precision Medicine
Yesterday
Funding
Element Biosciences raises USD 277 million in Series D funding to commercialize AVITI DNA sequencer and support AVITI24 launch
Precision Medicine
Yesterday
Funding
Jacobi Robotics raises USD 5 million in seed funding to expand capacity
Smart Factory
Yesterday
M&A
Formlabs acquires Micronics for undisclosed sum to develop next-generation SLS printers
Additive Manufacturing
Yesterday
Partnerships
Anthropic partners with Amazon Bedrock to fine-tune Claude 3 Haiku model
Foundation Models
Yesterday
Funding
Lemon.markets raises EUR 12 million in funding to support growth
FinTech Infrastructure
Yesterday
M&A
Kipu Quantum acquires PlanQK platform to enhance accessibility to quantum computing solutions
Quantum Computing
Yesterday
Partnerships
Quantinuum and STFC Hartree Centre partner to enhance quantum computing accessibility in UK
Quantum Computing
Yesterday
Precision Medicine

Precision Medicine

Jun 25, 2024

Tempus AI collaborates with United Therapeutics to develop AI-based risk detection for pulmonary hypertension

Partnerships

  • Tempus AI has partnered with United Therapeutics to develop medical device software that uses AI to detect early-stage pulmonary hypertension (PH).

  • The partnership expects to study the use of AI to identify individuals at risk of undiagnosed PH via analysis of electrocardiogram results. Tempus' AI-powered care pathway intelligence solution, Tempus Next, will be used in the deployment process for a prospective clinical study, conducted among 60 selected centers. During the study, clinicians will evaluate the product’s ability to detect patients at risk of undiagnosed PH and track clinical outcomes of patients identified for further evaluation. The study aims to provide novel solutions to expedite diagnosis and enhance patient outcomes.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.